glp-1 pdb RCSB Structure of the GLP-1 receptor

Meta-analyses have confirmed the benefit of GLP-1 RAs as a class in both secondary and primary prevention of cardiovascular disease, and in reduction of adverse kidney outcomes in people with T2D (Kristiensen et al, 2019

Interventions that address both menopause-driven metabolic risk and aging biology could shift not just the number of years lived, but the quality of those years

In 2025 and 2026 the two programs moved in opposite directions

demonstrated that semaglutide had similar effects in an ovariectomized rat model, increasing -catenin expression and reducing RANKL production, which resulted in a net increase in bone formation

A control group was administered with saline

*Obesity GLP-1 Wegovy and Zepbound Source: IQVIA Analysis